Literature DB >> 10195874

Cardiovascular risk factors and diseases after renal transplantation.

S Aker1, K Ivens, B Grabensee, P Heering.   

Abstract

UNLABELLED: Cardiovascular disease is a leading cause of death after renal transplantation (tpx), and the incidence is considerably higher than in the general population.
OBJECTIVE: To evaluate the incidence of atherosclerotic cardiovascular complications after tpx, the prevalence of cardiovascular risk factors, prior to and following tpx, and the association between the risk factors and complications. PATIENTS AND METHODS: Analysis of atherosclerotic cardiovascular diseases (coronary artery disease, cerebral and peripheral vascular disease) and cardiovascular risk factors before and after transplantation in 427 renal transplant recipients between 1987 and 1992 (mean age at transplantation 45+/-12 years, 58% male, 7% diabetics) with a mean post-transplant follow-up of 29+/-20 months.
RESULTS: Following tpx 11.7% developed atherosclerotic cardiovascular diseases, the majority coronary artery disease (9.8%). The comparison of risk factors 12 months before and 24 months following transplantation showed: prevalence of systemic hypertension (from 73% to 85%), diabetes mellitus (from 7% to 16%) and obesity with a body mass index >25 kg/m2 (from 26% to 48%) had increased significantly whereas the number of smokers halved to 20%. Triglycerides decreased significantly (from 235 mg/dl to 217 mg/dl). Total and HDL cholesterol rose significantly (from 232 mg/dl to 273 mg/dl and from 47 mg/dl to 56 mg/dl, respectively). LDL cholesterol increase was significant (from 180 mg/dl to 189 mg/dl). In the univariate analysis, cardiovascular diseases were significantly associated with male gender, age over 50 years, diabetes mellitus (DM), smoking, total cholesterol > or=200 mg/dl, LDL cholesterol >180 mg/dl, HDL cholesterol < or =55 mg/dl, fibrinogen > or =350 mg/dl, body mass index >25 kg/m2, serum uric acid >6.5 mg/dl and with more than two antihypertensive agents per day. The Cox proportional hazards model revealed DM with a relative risk (RR) of 4.3, age >50 years (RR=2.7), body mass index >25 kg/m2 (RR=2.6), smoking (RR=2.5), LDL cholesterol >180 mg/dl (RR=2.3) and uric acid >6.5 mg/dl as independent risk factors.
CONCLUSIONS: The high incidence of cardiovascular disease following renal transplantation is mainly due to a high prevalence and accumulation of classical risk factors before and following transplantation. Future prospective studies should evaluate the success of treatment regarding reduction of cardiovascular morbidity and mortality in this high risk population.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10195874     DOI: 10.1007/bf02564867

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  34 in total

1.  Changes in causes of death after renal transplantation, 1966 to 1987.

Authors:  M N Hill; R A Grossman; H I Feldman; S Hurwitz; D C Dafoe
Journal:  Am J Kidney Dis       Date:  1991-05       Impact factor: 8.860

Review 2.  Hyperlipidemia in solid organ transplantation.

Authors:  J A Kobashigawa; B L Kasiske
Journal:  Transplantation       Date:  1997-02-15       Impact factor: 4.939

3.  Development of an index to predict posttransplant diabetes mellitus.

Authors:  D K Hathaway; E A Tolley; M L Blakely; R P Winsett; A O Gaber
Journal:  Clin Transplant       Date:  1993       Impact factor: 2.863

4.  Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.

Authors:  D J Norman; D R Illingworth; J Munson; J Hosenpud
Journal:  N Engl J Med       Date:  1988-01-07       Impact factor: 91.245

Review 5.  Post-transplant hypertension.

Authors:  D A Laskow; J J Curtis
Journal:  Am J Hypertens       Date:  1990-09       Impact factor: 2.689

Review 6.  Cyclosporine-induced hypertension after transplantation.

Authors:  S C Textor; V J Canzanello; S J Taler; D J Wilson; L L Schwartz; J E Augustine; J M Raymer; J C Romero; R H Wiesner; R A Krom
Journal:  Mayo Clin Proc       Date:  1994-12       Impact factor: 7.616

7.  Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients.

Authors:  M Arnadottir; L O Eriksson; J I Germershausen; H Thysell
Journal:  Nephron       Date:  1994       Impact factor: 2.847

8.  Dialysis-associated ischemic heart disease: insights from coronary angiography.

Authors:  S G Rostand; K A Kirk; E A Rutsky
Journal:  Kidney Int       Date:  1984-04       Impact factor: 10.612

Review 9.  Established risk factors and coronary artery disease: the Framingham Study.

Authors:  P W Wilson
Journal:  Am J Hypertens       Date:  1994-07       Impact factor: 2.689

10.  Posttransplant hyperglycemia. Increased incidence in cyclosporine-treated renal allograft recipients.

Authors:  D Roth; M Milgrom; V Esquenazi; L Fuller; G Burke; J Miller
Journal:  Transplantation       Date:  1989-02       Impact factor: 4.939

View more
  10 in total

Review 1.  Calcineurin inhibitors and post-transplant hyperlipidaemias.

Authors:  R Moore; D Hernandez; H Valantine
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Obesity and cardiac risk after kidney transplantation: experience at one center and comprehensive literature review.

Authors:  Krista L Lentine; Lisa A Rocca-Rey; Giuliana Bacchi; Nadia Wasi; Leslie Schmitz; Paolo R Salvalaggio; Kevin C Abbott; Mark A Schnitzler; Luca Neri; Daniel C Brennan
Journal:  Transplantation       Date:  2008-07-27       Impact factor: 4.939

3.  Statin use is associated with prolonged survival of renal transplant recipients.

Authors:  Franz Wiesbauer; Georg Heinze; Christa Mitterbauer; Franz Harnoncourt; Walter H Hörl; Rainer Oberbauer
Journal:  J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 10.121

Review 4.  [Diabetes and heart transplantation].

Authors:  M Loebe; K Ramasubbu; D J Hamilton
Journal:  Clin Res Cardiol       Date:  2006-01       Impact factor: 5.460

Review 5.  The metabolic effects of cyclosporin and tacrolimus.

Authors:  P Marchetti; R Navalesi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

6.  Association of pre-transplant dialysis duration with outcome in kidney transplant recipients: a prevalent cohort study.

Authors:  Adam Remport; Andras Keszei; Eszter Panna Vamos; Marta Novak; Jeno Jaray; Laszlo Rosivall; Istvan Mucsi; Miklos Zsolt Molnar
Journal:  Int Urol Nephrol       Date:  2010-01-08       Impact factor: 2.370

Review 7.  HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Authors:  Suetonia C Palmer; Sankar D Navaneethan; Jonathan C Craig; Vlado Perkovic; David W Johnson; Sagar U Nigwekar; Jorgen Hegbrant; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2014-01-28

8.  An assessment of the long-term health outcome of renal transplant recipients in Ireland.

Authors:  A Al-Aradi; P J Phelan; P O'Kelly; A H Khan; M A Rahman; A Hanley; C Ho; F Kheradmand; D Hickey; S Spencer; C Magee; J J Walshe; N Morgan; P J Conlon
Journal:  Ir J Med Sci       Date:  2009-12       Impact factor: 2.089

9.  Kidney Function as a Determinant of HDL and Triglyceride Concentrations in the Australian Population.

Authors:  Michael Thompson; Udayan Ray; Richard Yu; Andrew Hudspeth; Michael Smillie; Neville Jordan; Janet Bartle
Journal:  J Clin Med       Date:  2016-03-08       Impact factor: 4.241

10.  Pre-Transplant Cardiovascular Risk Factors Affect Kidney Allograft Survival: A Multi-Center Study in Korea.

Authors:  Jung Nam An; Song Vogue Ahn; Jung Pyo Lee; Eunjin Bae; Eunjeong Kang; Hack-Lyoung Kim; Yong-Jin Kim; Yun Kyu Oh; Yon Su Kim; Young Hoon Kim; Chun Soo Lim
Journal:  PLoS One       Date:  2016-08-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.